DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients

Information source: The Cleveland Clinic
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Postoperative Kidney Injury

Intervention: human albumin 5% (Drug); HES 130/0.4 (Voluven) (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: The Cleveland Clinic

Official(s) and/or principal investigator(s):
Andra Duncan, M.D., Principal Investigator, Affiliation: The Cleveland Clinic

Overall contact:
Andra Duncan, M.D., Phone: 216-445-2372, Email: duncana@ccf.org


The purpose of this study is to evaluate the safety of a standard volume replacement called HES 130/0. 4 (Voluven) during surgery on recovery. HES 130/0. 4 (Voluven) may offer an alternative to pure fluid replacement solutions that are associated with problems after surgery including fluid overload and respiratory difficulties. The safety of HES 130/0. 4 (Voluven) will be evaluated by examining its effects on kidney function, and coagulation parameters and platelet (part of the blood that help it clot) function. Participants will be randomized (like flipping a coin) to receive one of two possible volume replacements during surgery, if fluid volume decreases enough to need replacement with one of the fluids. The two possible volume replacements are Voluven (a starch-containing fluid) or human albumin 5% (a protein-containing solution). To examine kidney function, urine will be-sampled when the participant is put under general anesthesia, before surgical incision, within one hour of arrival to the ICU and 24 hours after completion of surgery. Two tubes (2 teaspoons) of blood (from an already established line) will be taken the morning of the surgery, within one hour of arrival to the ICU, 24 hours after surgery and every morning during the participants postoperative ICU stay. Additionally, health and recovery information will be recorded from the participant's medical record. We will phone participants around 90 days and one year after surgery to ask a few questions about one's health and recovery. We will also record blood sample analysis results from follow up appointments within the first year after surgery. If this analysis is not conducted at the Cleveland Clinic, with permission, we will obtain the results from a treating physician.

Clinical Details

Official title: A Randomized Controlled Investigation of the Effects of 6% Hydroxyethylstarch 130/0.4 (Voluven) on Renal Function in Patients Having Aortic Valve Replacement With or Without Coronary Artery Bypass Grafting

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Urine neutrophil gelatinase-associated lipocalin (NGAL) [Time Frame: 24 hours after surgery] [Designated as safety issue: Yes]

Secondary outcome: coagulation parameters and measures of platelet aggregation


Minimum age: 40 Years. Maximum age: 85 Years. Gender(s): Both.


Inclusion Criteria:

- Age 50 - 85 years old

- Scheduled for elective aortic valve replacement with or without coronary artery

bypass grafting with or without additional minor surgical procedure.

- Written, informed consent for participation in this investigation.

Exclusion Criteria:

- Patients with renal failure with oliguria or anuria not related to hypovolemia.

- Patients receiving dialysis.

- Patients with preoperative renal insufficiency (Creatinine > 1. 6 mg/dL)

- Anticipated deep hypothermic circulatory arrest

- Known hypersensitivity or allergy to hydroxyethyl starch or the excipients of

hydroxyethyl starch

- Clinical conditions with volume overload (e. g., patients in pulmonary edema or

congestive heart failure)

- Patients with severe hypernatremia or severe hyperchloremia

- Patients with intracranial bleeding

- Pregnant or breast feeding women

- Critically ill adult patients, including patients with sepsis, due to increased risk

of mortality and renal replacement therapy, (e. g. patients who are hospitalized in the intensive care unit prior to surgery)

- Severe liver disease

- Pre-existing coagulation or bleeding disorders

- Any contraindications to proposed interventions.

Locations and Contacts

Andra Duncan, M.D., Phone: 216-445-2372, Email: duncana@ccf.org

Cleveland Clinic Foundation, Cleveland, Ohio 44195, United States; Recruiting
Andra Duncan, M.D., Phone: 216-445-2372, Email: duncana@ccf.org
Roberta Johnson, Phone: 216-444-9950, Email: johnsor13@ccf.org
Andra Duncan, M.D., Principal Investigator
Additional Information

Starting date: March 2015
Last updated: March 10, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017